NAD+ injections for energy and aging: what the evidence shows
Quick answer
NAD+ injections are not FDA-approved for any specific indication and are typically obtained through compounding pharmacies outside standard clinical oversight. The creator's route-of-administration hierarchy reflects basic pharmacokinetic logic, but no published human trials have directly compared sub-Q versus IM versus IV NAD+ on efficacy or absorption outcomes. Any perceived effects within days of starting injections should be interpreted cautiously given strong expectation bias inherent in unblinded self-experimentation.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @lose.weight.with.kate actually say?
The creator said she's taking NAD+ injections that came with instructions for either intramuscular (IM) or subcutaneous (sub-Q) administration. Because she's already familiar with sub-Q from GLP-1 shots, she's starting there. She added that she's "already noticed the difference" and that IM might be more effective, but IV is "definitely the best way" — something she attributes to celebrities — while calling it too expensive and inconvenient for her budget.
This is a pretty honest, experience-first framing. She's not selling anything, and she's clear about what she knows versus what she's heard. That matters when we're evaluating credibility. She's also working with instructions from whoever supplied her injections, which raises its own set of questions about sourcing and oversight.
Does the science back this up?
Partially. The IV-versus-injection hierarchy she describes has some biological plausibility, but the human evidence is thin across all three routes. Most clinical research on NAD+ precursors uses oral formulations, not injections, and head-to-head comparison studies between administration routes in humans basically don't exist yet.
NAD+ itself does not survive oral ingestion well because it's broken down in the gut before reaching systemic circulation. That's the argument for injectable routes. A 2023 review by Covarrubias et al. in Nature Aging noted that while NAD+ boosting strategies show metabolic and neuroprotective signals in animal models, translation to human outcomes remains early-stage. IV infusions do bypass first-pass metabolism entirely, which is the pharmacokinetic argument for their superiority. But whether sub-Q absorption is meaningfully inferior to IM for NAD+ specifically has not been tested in any published randomized trial. The creator's claim that IM is more effective than sub-Q is biologically reasonable but not yet evidence-confirmed.
What did they get wrong (or right)?
She got the general hierarchy roughly right on pharmacokinetic logic, even if she didn't know the mechanism. IV does deliver the fastest, most complete absorption. IM generally absorbs faster than sub-Q because muscle tissue is more vascularized. That part checks out as plausible science.
Where she's on shakier ground: saying she's "already noticed the difference" after starting sub-Q injections. That's a personal observation with no baseline measurement, no control, and a strong expectation effect baked in. This is not a criticism unique to her. It's the core problem with self-reported outcomes in unblinded, uncontrolled self-experimentation. The placebo response to injections specifically is well-documented and tends to be stronger than for oral interventions (Schedlowski et al., 2015, Pharmacological Reviews).
She also frames IV as what "all the celebrities do," which is a credibility appeal that doesn't mean much scientifically. IV NAD+ clinics are a wellness industry product, not an FDA-regulated therapy with a proven outcomes record.
What should you actually know?
A few things worth understanding if you're looking at NAD+ injections yourself. First, NAD+ is not a peptide despite being grouped in peptide-adjacent biohacking content. It's a coenzyme. Second, injectable NAD+ sits outside FDA-approved indications and is typically administered through compounding pharmacies or grey-market suppliers, which means quality control varies significantly. Third, IV NAD+ infusions are associated with side effects including nausea, chest tightness, and flushing, which are less commonly reported with IM or sub-Q routes (Braidy et al., 2019, Antioxidants and Redox Signaling).
The honest summary: the route-of-administration logic the creator outlines is pharmacologically coherent. But the idea that any route of NAD+ supplementation produces a noticeable subjective effect within days is not well-supported by controlled human data. If you're considering this, that conversation belongs with a licensed clinician who can assess your individual situation, not a TikTok comment thread.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
NAD+ Peptide Complex access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For NAD+ injections for energy and aging: what the evidence shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis
Supports careful discussion of semaglutide in NASH-related cirrhosis without overstating outcomes.
PubMed
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis
Used for liver-disease pages where semaglutide appears in exploratory NASH combination research.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
NAD+ Peptide Complex is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this nad+ video claims cluster
Best for searchers separating NAD+ longevity marketing from practical metabolic and safety questions.
Claim verdict
The useful answer behind this video
Claim being checked
NAD+ injections are not FDA-approved for any specific indication and are typically obtained through compounding pharmacies outside standard clinical oversight.
FormBlends verdict
NAD+ injections are not FDA-approved for any specific indication and are typically obtained through compounding pharmacies outside standard clinical oversight. The creator's route-of-administration hierarchy reflects basic pharmacokinetic logic, but no published human trials have directly compared sub-Q versus IM versus IV NAD+ on efficacy or absorption outcomes. Any perceived effects within days of starting injections should be interpreted cautiously given strong expectation bias inherent in unblinded self-experimentation.
Patient-safe next step
Compare the claim with the NAD+ Peptide Complex guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- NAD+ injections are not FDA-approved for any specific indication and are typically obtained through compounding pharmacies outside standard clinical oversight. The creator's route-of-administration hierarchy reflects basic pharmacokinetic logic, but no published human trials have directly compared sub-Q versus IM versus IV NAD+ on efficacy or absorption outcomes. Any perceived effects within days of starting injections should be interpreted cautiously given strong expectation bias inherent in unblinded self-experimentation.
- NAD+ is a coenzyme, not a peptide. It's frequently grouped with peptide biohacking content but belongs to a distinct biochemical category.
- No published randomized human trial has compared sub-Q versus IM versus IV routes for NAD+ absorption or clinical outcomes as of 2024.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- NAD+ Peptide Complex decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the NAD+ Peptide Complex guide, cost path, safety notes, and provider review before acting.
Review NAD+ Peptide ComplexWhat You'll Learn
- NAD+ is a coenzyme, not a peptide. It's frequently grouped with peptide biohacking content but belongs to a distinct biochemical category.
- No published randomized human trial has compared sub-Q versus IM versus IV routes for NAD+ absorption or clinical outcomes as of 2024.
- IV administration offers 100% bioavailability by bypassing gut and liver metabolism, which is the pharmacokinetic basis for its perceived superiority. This is logical but not yet proven superior in clinical outcome data.
- Placebo responses to injections are measurably stronger than to oral interventions (Schedlowski et al., 2015, Pharmacological Reviews), which complicates any self-reported 'I noticed a difference' observation without controls.
- Injectable NAD+ is not FDA-approved for any indication and is typically sourced through compounding pharmacies, meaning product purity and dosing consistency are not federally regulated.
- IV NAD+ infusions carry documented side effects including nausea, flushing, and chest tightness that are less commonly reported with sub-Q or IM routes (Braidy et al., 2019, Antioxidants and Redox Signaling).
- Most peer-reviewed NAD+ research in humans uses oral precursors like NMN or NR, not injectable NAD+. Extrapolating from that literature to injection outcomes requires significant caution.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Kate’s GLP Journey · TikTok creator
1.6K views on this video
Replying to @Kristen NAD+ Injections SUB-Q, IM or IV? 🩷💕🫶 #myjourney #nad #glowup #glowupjourney #peptide #biohacking #selfimprovement #glp1
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Kate’s GLP Journey, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.